Inactive Instrument

Analyst Reco. ACLS THER Nasdaq

Equities

End-of-day quote Nasdaq Other stock markets
- ^USD	-

05-07	Transcript : Aclaris Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024
05-07	Earnings Flash (ACRS) ACLARIS THERAPEUTICS Reports Q1 Revenue $2.4M, vs. Street Est of $2M	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Downgrades Aclaris Therapeutics to Neutral From Buy	01-22	MT
BTIG Downgrades Aclaris Therapeutics to Neutral From Buy	01-11	MT
Stifel Trims Price Target on Aclaris Therapeutics to $1 From $2, Maintains Hold Rating	12-18	MT
HC Wainwright Cuts Price Target on Aclaris Therapeutics to $9 From $43, Maintains Buy Rating	11-14	MT
Cantor Fitzgerald Downgrades Aclaris Therapeutics to Neutral From Overweight	11-14	MT
Evercore ISI Cuts Aclaris Therapeutics' Price Target to $3 From $22, Keeps Outperform Rating	11-13	MT
Piper Sandler Downgrades Aclaris Therapeutics to Neutral From Overweight, Cuts Price Target to $2 From $30	11-13	MT
Stifel Downgrades Aclaris Therapeutics to Hold From Buy, Cuts Price Target to $2 From $20	11-13	MT
William Blair Downgrades Aclaris Therapeutics to Market Perform From Outperform	11-13	MT
Evercore ISI Initiates Aclaris Therapeutics at Outperform Rating With $22 Price Target	23-10-03	MT
Stifel Adjusts Price Target on Aclaris Therapeutics to $20 From $16, Maintains Buy Rating	23-09-14	MT
Goldman Sachs Adjusts Price Target on Aclaris Therapeutics to $21 From $25, Maintains Buy Rating	23-03-07	MT
HC Wainwright Adjusts Price Target on Aclaris Therapeutics to $43 From $50, Maintains Buy Rating	23-03-07	MT
BTIG Research Adjusts Aclaris Therapeutics Price Target to $29 From $32, Maintains Buy Rating	23-03-07	MT
Stifel Nicolaus Initiates Coverage on Aclaris Therapeutics With Buy Rating, $29 Price Target	22-12-14	MT
Goldman Sachs Initiates Aclaris Therapeutics at Buy With $25 Price Target	22-12-01	MT
BTIG Starts Aclaris Therapeutics at Buy With $32 Price Target	22-10-06	MT
ACLARIS THERAPEUTICS : HC Wainwright Adjusts Price Target on Aclaris Therapeutics to $50 From $40, Reiterates Buy Rating	21-06-16	MT
ACLARIS THERAPEUTICS : Piper Sandler Starts Aclaris Therapeutics at Overweight With $30 Price Target	21-06-15	MT
ACLARIS THERAPEUTICS : HC Wainwright Initiates Aclaris Therapeutics at Buy Rating With $40 Price Target	21-04-21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. ACLS THER Nasdaq

Equities

Analyst Reco.

Filters